NCT04616248View on ClinicalTrials.gov

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

January 9, 2026

Study Completion Date

January 9, 2027

Conditions
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8Unresectable Breast CarcinomaMetastatic MelanomaUnresectable MelanomaCutaneous Squamous Cell CarcinomaMerkel Cell CarcinomaSoft Tissue SarcomaBone SarcomaSarcoma,Soft TissueSarcoma of BoneBasal Cell Carcinoma
Interventions
BIOLOGICAL

Anti-CD40 Agonist Monoclonal Antibody CDX-1140

Given IT

DRUG

Poly ICLC

Given IT

RADIATION

Radiation Therapy

Undergo radiation therapy

BIOLOGICAL

Recombinant Flt3 Ligand

Given IT

DRUG

Pembrolizumab

Given IV

DRUG

Tocilizumab

Given SC

Trial Locations (2)

90033

RECRUITING

Los Angeles General Medical Center, Los Angeles

RECRUITING

USC/Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of Southern California

OTHER